文献速递膀胱癌与上尿路尿路上皮癌

高危肌层浸润性尿路上皮癌根治性切除术后辅助纳武利尤单抗的健康相关生活质量:3期CheckMate 274试验结果

Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial.
PubMed 文献 · Eur Urol Oncol · 2022-03-11

基于CheckMate 274试验709例患者(其中282例PD-L1表达≥1%),评估辅助纳武利尤单抗对肌层浸润性尿路上皮癌根治性切除术后健康相关生活质量的影响。全生活质量可评估人群中,两组均未见临床有意义的生活质量恶化,纳武利尤单抗在所有主要结局的基线变化上非劣于安慰剂。

要点

  • 全生活质量可评估人群中,纳武利尤单抗组与安慰剂组均未见临床有意义的生活质量恶化。
  • 纳武利尤单抗在所有主要结局的基线变化上非劣于安慰剂。
  • 乏力至确认恶化的中位时间:纳武利尤单抗组41.0周 vs 安慰剂组44.3周(HR 1.11,95%CI 0.89-1.39)。

核心结论

  • 纳武利尤单抗未损害CheckMate 274中肌层浸润性尿路上皮癌患者的生活质量。

研究设计与样本

  • CheckMate 274(NCT02632409)是一项正在进行的随机、双盲、安慰剂对照3期试验,共纳入709例患者,其中282例PD-L1表达≥1%。
  • 干预为每2周静脉注射纳武利尤单抗240 mg或安慰剂,最长1年。
  • 采用EORTC QLQ-C30和EQ-5D-3L评估健康相关生活质量,使用线性混合效应模型比较两组生活质量变化,采用Cox比例风险回归分析至确认恶化时间。

主要发现

  • 全生活质量可评估人群中,纳武利尤单抗组与安慰剂组均未观察到临床有意义的生活质量恶化。
  • 纳武利尤单抗在所有主要结局的基线变化上非劣于安慰剂。
  • 乏力至确认恶化的中位时间:纳武利尤单抗组41.0周 vs 安慰剂组44.3周(HR 1.11,95%CI 0.89-1.39)。
  • 视觉模拟量表至确认恶化的中位时间:纳武利尤单抗组未达到 vs 安慰剂组57.6周(HR 0.78,95%CI 0.61-1.00)。
  • 其他主要结局至确认恶化的中位时间在两组均未达到;PD-L1表达≥1%患者中结果相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The programmed death-1 (PD-1) inhibitor nivolumab prolongs disease-free survival in patients with muscle-invasive urothelial carcinoma (MIUC). OBJECTIVE: To evaluate the effects of nivolumab on health-related quality of life (HRQoL) after radical resection in patients with MIUC. DESIGN, SETTING, AND PARTICIPANTS: We used data from 709 patients in CheckMate 274 (NCT02632409; 282 with programmed death ligand 1 [PD-L1] expression ≥1%), an ongoing randomized, double-blind, placebo-controlled phase 3 trial of adjuvant nivolumab. INTERVENTION: Intravenous injection of nivolumab (240 mg) or placebo every 2 wk for ≤1 yr. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the EQ-5D-3L. Linear mixed-effect models for repeated measures were used to compare nivolumab and placebo on changes in HRQoL. Time to confirmed deterioration (TTCD) of HRQoL was analyzed by Cox proportional hazards regression. RESULTS AND LIMITATIONS: In the full HRQoL evaluable population, no clinically meaningful deterioration of HRQoL was observed in either treatment arm. Moreover, nivolumab was noninferior to placebo on changes from baseline for all main outcomes. The median TTCD for fatigue was 41.0 wk for nivolumab and 44.3 wk for placebo (hazard ratio [HR]: 1.11, 95% confidence interval [CI], 0.89-1.39). For the visual analog scale, the median TTCD was not reached for nivolumab and it was 57.6 wk for placebo (HR: 0.78, 95% CI, 0.61-1.00). The median TTCD for the other main outcomes was not reached in either treatment arm. The findings were similar for patients with PD-L1 expression ≥1%. CONCLUSIONS: These results demonstrate that nivolumab did not compromise the HRQoL of patients with MIUC in CheckMate 274. PATIENT SUMMARY: Nivolumab is being researched as a new treatment for patients with bladder cancer (urothelial carcinoma). We found that nivolumab maintained quality of life while increasing the time until cancer returns in patients whose bladder cancer had spread or grown and who had unsuccessfully tried platinum-containing chemotherapy.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Witjes JA, Galsky MD, Gschwend JE, et al. Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial. Eur Urol Oncol. 2022. PMID: 35288066. doi:10.1016/j.euo.2022.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。